Demographic, transplant, geriatric, and laboratory characteristics
| Characteristic . | No. . | % . |
|---|---|---|
| No. of patients | 527 | |
| Median follow-up of survivors (range), mo | 46 (8-143) | |
| Median age (range), y | 65 (60-78.7) | |
| Female sex | 203 | 39 |
| Transplant diagnosis | ||
| AML | 210 | 40 |
| ALL | 28 | 5 |
| MDS | 120 | 23 |
| Lymphoma | 94 | 18 |
| Other hematologic malignancies | 75 | 14 |
| KPS ≥90 | 261 | 50 |
| HCT-CI | ||
| 0-2 | 233 | 44 |
| ≥3 | 294 | 56 |
| DRI revised | ||
| Low/intermediate | 386 | 73 |
| High/very high | 141 | 27 |
| Graft type | ||
| Bone marrow | 40 | 8 |
| Peripheral blood | 453 | 86 |
| Cord blood | 34 | 6 |
| Donor type | ||
| Match related | 156 | 30 |
| Match unrelated | 242 | 46 |
| Cord blood | 34 | 6 |
| Mismatched (≤7/8) unrelated | 81 | 15 |
| Haploidentical | 14 | 3 |
| Conditioning intensity | ||
| Myeloablative | 327 | 62 |
| Nonmyeloablative/reduced intensity | 200 | 38 |
| Recipient CMV status | ||
| Negative | 208 | 39 |
| Positive | 319 | 61 |
| GVHD prophylaxis | ||
| Ex vivo CD34+ selected | 241 | 46 |
| Unmodified | 265 | 50 |
| Posttransplant cyclophosphamide | 21 | 4 |
| ADL | ||
| Normal | 507 | 96 |
| Impaired | 20 | 4 |
| Potentially inappropriate use of medication | ||
| No | 284 | 54 |
| Yes | 243 | 46 |
| Falls within last year | ||
| No | 427 | 81 |
| Yes | 99 | 19 |
| Weight loss of 10 pounds in the last 3 mo | ||
| No | 435 | 83 |
| Yes | 92 | 17 |
| Albumin level, g/dL | ||
| <3.5 | 31 | 6 |
| ≥3.5 | 496 | 94 |
| Platelet count on admission, ×109/L | ||
| ≥50 | 459 | 87 |
| <50 | 68 | 13 |
| Creatinine clearance, mL/min | ||
| ≥60 | 472 | 90 |
| <60 | 55 | 10 |
| Characteristic . | No. . | % . |
|---|---|---|
| No. of patients | 527 | |
| Median follow-up of survivors (range), mo | 46 (8-143) | |
| Median age (range), y | 65 (60-78.7) | |
| Female sex | 203 | 39 |
| Transplant diagnosis | ||
| AML | 210 | 40 |
| ALL | 28 | 5 |
| MDS | 120 | 23 |
| Lymphoma | 94 | 18 |
| Other hematologic malignancies | 75 | 14 |
| KPS ≥90 | 261 | 50 |
| HCT-CI | ||
| 0-2 | 233 | 44 |
| ≥3 | 294 | 56 |
| DRI revised | ||
| Low/intermediate | 386 | 73 |
| High/very high | 141 | 27 |
| Graft type | ||
| Bone marrow | 40 | 8 |
| Peripheral blood | 453 | 86 |
| Cord blood | 34 | 6 |
| Donor type | ||
| Match related | 156 | 30 |
| Match unrelated | 242 | 46 |
| Cord blood | 34 | 6 |
| Mismatched (≤7/8) unrelated | 81 | 15 |
| Haploidentical | 14 | 3 |
| Conditioning intensity | ||
| Myeloablative | 327 | 62 |
| Nonmyeloablative/reduced intensity | 200 | 38 |
| Recipient CMV status | ||
| Negative | 208 | 39 |
| Positive | 319 | 61 |
| GVHD prophylaxis | ||
| Ex vivo CD34+ selected | 241 | 46 |
| Unmodified | 265 | 50 |
| Posttransplant cyclophosphamide | 21 | 4 |
| ADL | ||
| Normal | 507 | 96 |
| Impaired | 20 | 4 |
| Potentially inappropriate use of medication | ||
| No | 284 | 54 |
| Yes | 243 | 46 |
| Falls within last year | ||
| No | 427 | 81 |
| Yes | 99 | 19 |
| Weight loss of 10 pounds in the last 3 mo | ||
| No | 435 | 83 |
| Yes | 92 | 17 |
| Albumin level, g/dL | ||
| <3.5 | 31 | 6 |
| ≥3.5 | 496 | 94 |
| Platelet count on admission, ×109/L | ||
| ≥50 | 459 | 87 |
| <50 | 68 | 13 |
| Creatinine clearance, mL/min | ||
| ≥60 | 472 | 90 |
| <60 | 55 | 10 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; GVHD, graft-versus-host disease; MDS, myelodysplastic syndrome.